Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Goserelin - AstraZeneca

Next Previous
Drug Profile

Goserelin - AstraZeneca

Alternative Names: Goserelin acetate - AstraZeneca; Goserelin acetate implant - AstraZeneca; ZD-9393; Zoladex

Latest Information Update: 02 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; TerSera Therapeutics
  • Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action LHRH receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 29 May 2026 Phase-I clinical trials in Breast cancer (Late-stage disease, Metastatic disease) in USA (SC) (NCT07310420)
  • 29 Dec 2025 TerSera Therapeutics LLC plans to initiate a phase I trial for Breast Cancer (Metastatic disease, Late-stage disease) (SC) (NCT07310420)
  • 07 May 2024 Health Canada approves sNDA for Goserelin 10.8mg every 12 weeks for the treatment of Breast cancer (Late-stage disease)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top